To date, CEPI has committed over $280 million to nine partnerships.

1. Up to $37.5m to Vienna-based Themis Bioscience to advance vaccines against Lassa fever and MERS.
2. Up to $56m to Inovio Pharmaceuticals Inc to support pre-clinical and clinical advancement through phase 2 of its Lassa fever and MERS vaccines.
3. $10.4m to support the first phase of a project by the International AIDS Vaccine Initiative (IAVI) for the development of its replicating viral vector-based Lassa vaccine candidate, rVSVΔG-LASV-GPC; CEPI has options to invest up to $54.9m over five years (including stockpile).
4. Two agreements, one for up to $25m and a second for up to $36m, with Profectus Biosciences and Emergent Biosolutions (Mary Lou McDonald’s brother – Bernie McDonald ex- employee) to develop Nipah virus and Lassa virus vaccines.
5. Up to $36m to IDT Biologika to develop a MERS vaccine.
6. Up to $19m to the Jenner Institute, at the University of Oxford, and Janssen Vaccines & Prevention BV (part of the Janssen Pharmaceutical Companies of Johnson & Johnson) to advance development and manufacturing of a vaccine against MERS. Preclinical development of novel vaccines against Lassa and Nipah viruses will also be part of this collaboration.
7. Up to $8.4m to Imperial College London to develop a self-amplifying RNA (saRNA) vaccine platform that enables tailored vaccine production against multiple viral pathogens.
8. Up to $10.6m to University of Queensland to develop a ‘molecular clamp’ vaccine platform that enables targeted and rapid vaccine production against multiple viral pathogens.